Testing Different Doses of BI 764532 Given by IV Infusions in Adults With DLL3 Positive Brain Tumors Glioma

What this Trial Is About

Researchers are evaluating the highest dose of BI 764532 that adults with a brain tumour positive for the tumour marker delta-like 3 DLL3 can tolerate. This study focuses on people with advanced glioma who have not responded to previous treatments. BI 764532 is an antibody-like molecule designed to connect cancer cells and immune system T-cells, potentially helping the immune system fight the tumour. Participants receive BI 764532 through intravenous infusions starting at treatment. If they benefit and tolerate the drug, the treatment continues with regular visits to the study site. The number of visits varies depending on individual response and tolerance. Early visits include monitoring participants safety closely. Throughout the study, doctors monitor general health and record any side effects. Safety assessments are performed regularly. The primary outcome is the occurrence of dose-limiting toxicity during the first up to 4 weeks of dosing. Secondary outcomes include safety over the entire treatment period of up to 26 months. Total participation time depends on treatment response and tolerance.

A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3